• Mashup Score: 1
    How Do the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 2 year(s) ago

    Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/eu4ZniFYgG

  • Mashup Score: 0
    Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis - 2 year(s) ago

    Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year’s ASCO meeting, Ian Davis presented the updated OS…

    Source: UroToday
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Overall survival outcomes in #ENZAMET (ANZUP 1304), a trial of enzalutamide in metastatic hormone-sensitive #ProstateCancer. @Prof_IanD @easternhealthau joins @CaPsurvivorship @DanaFarber in discussion on UroToday > https://t.co/43pqUKCHRS https://t.co/q5QXannwRJ

  • Mashup Score: 4
    Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen - 2 year(s) ago

    Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Health-related QoL - The #ENZAMET trial. A UroToday #JournalClub discussion with @WallisCJD @UofT & @zklaassen_md @GACancerCenter of the @JCO_ASCO publication. #WatchNow > https://t.co/YC0SbAdAaL @ANZUPtrials https://t.co/lLYoloQnIU

  • Mashup Score: 4
    Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen - 2 year(s) ago

    Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Health-related QoL - The #ENZAMET trial. A UroToday #JournalClub discussion with @WallisCJD @UofT & @zklaassen_md @GACancerCenter of the @JCO_ASCO publication. #WatchNow > https://t.co/YC0SbAdAaL @ANZUPtrials https://t.co/jByIEYWqHz

  • Mashup Score: 4
    Program Guide – ASCO Meeting Program Guide - 2 year(s) ago

    AuthorsIan D. DavisEastern Health Clinical School, Monash University, Box Hill, AustraliaIan D. Davis, Andrew James Martin, Robert Richard Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David William Pook, Francis Parnis, Scott A. North, Gavin M. Marx, John McCaffrey, Raymond S. McDermott, Nicola Jane Lawrence, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim…

    Source: meetings.asco.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of crisbergerot
      crisbergerot

      🔥 @ASCO Daily News #ASCO22 @Prof_IanD #ENZAMET - Update confirms OS benefit w enzalutamide in metastatic hormone-sensitive prostate cancer Abstract: https://t.co/h50Dec5CzH Daily News: https://t.co/9We7h5uW0W https://t.co/OR3Rv9hA7u

  • Mashup Score: 3
    Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen - 2 year(s) ago

    Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Health-related QoL - The #ENZAMET trial. A UroToday #JournalClub discussion with @WallisCJD @UofT & @zklaassen_md @GACancerCenter of the @JCO_ASCO publication. #WatchNow > https://t.co/YC0SbAdAaL @ANZUPtrials https://t.co/92TMSSefv6

  • Mashup Score: 0
    Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen - 2 year(s) ago

    Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until…

    Source: UroToday
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Health-related QoL - The #ENZAMET trial. A UroToday #JournalClub discussion with @WallisCJD @UofT & @zklaassen_md @GACancerCenter of the @JCO_ASCO publication. #WatchNow > https://t.co/YC0SbAdAaL @ANZUPtrials https://t.co/dtOEbmvIex

Load More